Creative Planning
CTIC

Creative Planning’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Creative Planning’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-12,573
Closed -$15K – 2323
2020
Q2 		$15K Sell
12,573
-37,500
-75% -$39.6K ﹤0.01% 1853
2020
Q1 		$46K Hold
50,073
– – ﹤0.01% 1648
2019
Q4 		$79K Hold
50,073
– – ﹤0.01% 1779
2019
Q3 		$42K Hold
50,073
– – ﹤0.01% 1809
2019
Q2 		$43K Hold
50,073
– – ﹤0.01% 1829
2019
Q1 		$49K Hold
50,073
– – ﹤0.01% 1780
2018
Q4 		$37K Sell
50,073
-1,500
-3% -$2.46K ﹤0.01% 1743
2018
Q3 		$111K Hold
51,573
– – ﹤0.01% 1774
2018
Q2 		$257K Sell
51,573
-1,025
-2% -$4.49K ﹤0.01% 1458
2018
Q1 		$205K Buy
52,598
+20,025
+61% +$70.4K ﹤0.01% 1602
2017
Q4 		$87K Hold
32,573
– – ﹤0.01% 1744
2017
Q3 		$104K Buy
32,573
+30,000
+1,166% +$100K ﹤0.01% 1713
2017
Q2 		$9K Sell
2,573
-9,100
-78% -$35.4K ﹤0.01% 3723
2017
Q1 		$49K Buy
+11,673
New +$53.9K ﹤0.01% 2494
2016
Q4 		– Sell
-9,174
Closed -$34K – 5098
2016
Q3 		$34K Hold
9,174
– – ﹤0.01% 2663
2016
Q2 		$31K Hold
9,174
– – ﹤0.01% 2482
2016
Q1 		$49K Hold
9,174
– – ﹤0.01% 2130
2015
Q4 		$113K Buy
9,174
+8,307
+958% +$111K ﹤0.01% 1562
2015
Q3 		$13K Buy
+867
New +$15K ﹤0.01% 3058
2015
Q2 		– Sell
-1,533
Closed -$28K – 4100
2015
Q1 		$28K Buy
1,533
+749
+96% +$16.9K ﹤0.01% 2464
2014
Q4 		$18K Buy
784
+50
+7% +$1.16K ﹤0.01% 2754
2014
Q3 		$18K Sell
734
-53
-7% -$1.38K ﹤0.01% 2624
2014
Q2 		$22K Buy
787
+210
+36% +$6.31K ﹤0.01% 2443
2014
Q1 		$20K Sell
577
-520
-47% -$17.8K ﹤0.01% 2391
2013
Q4 		$21K Buy
1,097
+50
+5% +$910 ﹤0.01% 2172
2013
Q3 		$17K Sell
1,047
-395
-27% -$4.58K ﹤0.01% 2200
2013
Q2 		$15K Buy
+1,442
New +$16.9K ﹤0.01% 2106

Other funds holding CTIC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Creative Planning's CTIC Position: Q3 2020 in Review

Creative Planning sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2020, closing a stake of 12,573 shares — an estimated $15K sold.

Creative Planning first reported a position in CTIC in Q2 2013 and held it in 27 quarters. The position peaked at $257K in Q2 2018. 38 funds tracked by Wall St. Rank hold CTIC as of Q3 2020.

  • Creative Planning reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2020 after selling out during the quarter.
  • Creative Planning sold 12,573 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2020, an estimated $15K.
  • Creative Planning first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 27 quarters.
  • Creative Planning's CTI BioPharma Corp. (DE) Common Stock position peaked at $257K in Q2 2018.
  • 38 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2020.

Based on Creative Planning's 13F filing for Q3 2020, filed 5 Nov 2020.